What Managed Care Needs to Know About Recent Real-World Evidence and Best Practices for CDK 4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer: Utilizing Recent Data for Optimal Decision Making

What Managed Care Needs to Know About Recent Real-World Evidence and Best Practices for CDK 4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer: Utilizing Recent Data for Optimal Decision Making is organized by National Association of Managed Care Physicians (NAMCP) and will be held from Jan 01, 2022 - Jan 01, 2024.,,Description:,Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. According to the National Cancer Institute, an estimated 281,550 new cases of invasive breast cancer are to be diagnosed in women in the United States during 2021. The incidence in women in the United States is 1 in 8 (about 13 percent). About 43,600 women are expected to die from breast cancer this year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. However, in the later stages of disease, when distant metastases are present, cure becomes less likely, and few patients are rendered free of disease. Fortunately for advanced breast cancer patients with HR+/HER2- advanced breast cancer, several new agents, including CDK 4/6 inhibitors, have changed the paradigm in the last 10 years, and recent real-world data has been released that shows the strong efficacy and safety of these options. This webinar series will provide managed care professionals and oncologists with the latest real-world data and strategies in the evolving treatment paradigm. Participants will leave with ability to understand and utilize recent real world and clinical trial data, implement best strategies, tackle first line treatment decisions, as well as the ability to help educate both their staff and colleagues, which will ultimately increase organizational quality and, most importantly, improve access and outcomes in patients with HR+/HER2- metastatic breast cancer.,,Upon completion of this activity, participants will be able to:,• Examine the unmet economic needs in HR+/HER2- metastatic breast cancer and the impact of inadequately treated disease on physical and mental health, quality of life, costs and work productivity,• Explore real-world evidence derived from real-world data supplementing clinical trial evidence related to the benefits and risks of CDK 4/6 inhibitors in HR+/HER2- metastatic breast cancer,• Formulate recommendations to ensure appropriate access for first-line treatment of HR+/HER2-metastatic breast cancer with CDK 4/6 inhibitors,• Assess the managed care considerations of CDK 4/6 inhibitors by exploring where these agents fit into current metastatic breast cancer management paradigm,• Transform therapeutic advances and resource utilization data on emerging therapies in alopecia areata into informed health plan decisions and formulary discussions,,Additional details will be posted as soon as information is available.